谷胱甘肽S-转移酶P1基因多态性与晚期结直肠癌化疗疗效的关系  

Genetic polymorphisms of glutathione S- transferase P1 predict clinical outcomes of advanced colorectal cancer treated with m FOL-FOX6 chemotherapy

作　　者：韩磊[1] 董宁宁[2] 

机构地区：[1]济宁医学院附属医院肿瘤科,山东济宁272000 [2]首都医科大学附属北京友谊医院消化内科国家消化系统疾病临床医学研究中心,北京100050

出　　处：《临床和实验医学杂志》2015年第7期542-545,共4页Journal of Clinical and Experimental Medicine

基　　金：首都医科大学基础临床科研合作基金(14JL35);首都医科大学附属北京友谊医院科研启动基金(YYQDKT2014-13)

摘　　要：目的探讨谷胱甘肽S-转移酶P1(GSTP1)基因多态性对晚期结直肠癌患者化疗疗效的预测价值。方法入组晚期结直肠癌病人71例,采用m FOLFOX6方案化疗,采用基质辅助激光解吸电离飞行时间确定GSTP1 rs1695基因型,用χ2检验分析基因型对客观有效率的影响,Kaplan-Merier法进行生存分析,对数秩检验分析不同基因型患者疾病进展时间的差异。结果携带GSTP1 rs1695 AA基因型晚期结直肠癌患者化疗客观有效率(完全缓解+部分缓解)显著高于AG/GG基因型(60.8%vs.30.0%,P=0.02),Kaplan-Meier生存分析显示携带GSTP1 rs1695 AA基因型患者疾病进展时间显著长于AG/AA基因型[8.1(95%CI:7.1-9.1)months vs.3.8(95%CI:0.3-7.3)months,P=0.001]。结论GSTP1基因型与晚期结直肠患者m FOLFOX6方案化疗疗效密切相关,了解GSTP1基因型可为结直肠癌患者的个体化治疗提供参考。Objective To investigate the association between genetic polymorphisms of glutathione S- transferase P1（ GSTP1） and clinical outcomes of m FOLFOX6 chemotherapy in patients with advanced colorectal cancer. Methods Genotypes of GSTP1 were determined by matrix- assisted laser desorption / ionization time- of- flight. χ^2 test was used for statistical analysis between genotype and objective response,and Log- rank test on PFS. Results Among 71 enrolled patients,people with GSTP1 rs1695 AA genotype showed both a statistically higher objective response than those with AG / GG genotype（ 60. 8% vs. 30. 0%,P = 0. 02）,and statistically longer PFS [8. 1（ 95% CI： 7. 1- 9. 1） months vs.3. 8（ 95% CI： 0. 3- 7. 3） months,P = 0. 001]. Conclusion GSTP1 rs1695 A〉G polymorphisms have a predictive and prognostic contribution towards m FOLFOX6 regimen in advanced colorectal cancer,which represents a further step towards personalized therapy.

关 键 词：结直肠癌 谷胱甘肽S-转移酶P1 基因多态性 化学治疗 

分 类 号：R735.34[医药卫生—肿瘤]